Ernest Marmer
Long only, special situations

Orexigen To Rise On Very Likely FDA Nod June 11th

Orexigen (NASDAQ:OREX) is looking at a PDUFA date of June 11 to find out from the FDA if it can bring its weight-control combo, NB32/Contrave (sustained-release bupropion/naltrexone), to market this summer. The major regulatory hurdle of FDA clearance for the US market is well known to provide a strong price movement whether up or down and in OREX's case it looks to be about 40-50% move either way. Does it work well enough to get that FDA nod? Is it safe enough for the FDA? Will it make appreciable sales once it does? Yes, yes, and yes.

FDA Reception Positive...

In December of 2010, an FDA advisory-committee panel reviewed Contrave's four Phase III studies and voted 13-7 that...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details